Clinical trial · Interventional
An Exploration of Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer
An Exploratory Study of Low-dose Apatinib Combined With S-1 in Patients With Advanced Non-small Cell Lung Cancer
NCT03129256CI-TRIAL-00042139EASEcompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study is to explore the potential efficacy and safety of low-dose Apatinib combined with S-1 in patients with advanced lung cancer. Patients with advanced NSCLC will be treated with oral apatinib and S-1 after treatment failure of standard regimen.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non-small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Apatinib Mesylate tablet combined with S-1 capsules | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Apatinib & S-1
- description
- Apatinib Mesylate tablet combined with S-1 Capsules Apatinib Mesylate tablet 250mg once daily combined with S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules) 40mg\~60mg twice daily by mouth, d1-14, repeated every 3 weeks.
- interventionNames
- Drug: Apatinib Mesylate tablet combined with S-1 capsules
Primary outcomes (1)
- measure
- Progression Free Survival(PFS)
- timeFrame
- 2 years
- description
- PFS is defined as the length of time from random assignment to disease progression or to death resulting from any cause other than the progress.
Secondary outcomes (4)
- measure
- Overall Survival(OS)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed Non-small cell lung cancer * Patients with extracranial measurable lesions * Patients with NSCLC failed for standard treatments * Eastern Cooperative Oncology Group performance status score: 0\~2 and life expectancy of more than 3 months * Major organs functioning properly * Compliance is good and agreed to cooperate with the survival of follow-up * Informed consent Exclusion Criteria: * Contraindications for investigational agents * Patients with clinical symptoms of brain metastases or meningeal metastasis * Tumor invade big vessels or close to big vessels * Uncontrolled hypertension * Abnormal coagulation (INR\>1.5 or Prothrombin Time\>ULN+4, or Activated Partial Thromboplastin Time\>1.5 ULN), bleeding tendency or receiving coagulation therapy * Hemoptysis, more than 2.5ml daily * Thrombosis in 12 months, including pulmonary thrombosis, stoke, or deep venous thrombosis. * Myocardial ischemia or infarction more than stage II, cardiac insufficiency. * Received big surgery, had bone fracture or ulcer in 4 weeks. * Urine protein≥++, or urine protein in 24 hours≥1.0g
References
Publications (0)
Data not yet available
No reference posted for this study.